Cancer Drug Development
They also look for new ways to use drugs that are already available. To do this, it must go through a long development and approval process. But the actual amount of time and money needed depends on the drug. When the results from preclinical and clinical studies suggest that a potential new drug is safe and effective, a company will submit a new drug application (NDA) to the FDA.6 This application includes all of the preclinical and clinical data for the new drug, as well as its proposed labeling, directions for use, patent information, safety updates, and potential for drug abuse or misuse. Once the FDA receives the application, it decides whether the application is complete or not. Incomplete applications are not filed and are not reviewed. Complete applications must be reviewed and a decision issued by the FDA within 6 to 10 months
High Impact List of Articles
-
Full-text publication rate of studies reported as 2013 SoFCOT meeting abstracts
Roger Erivan -
Full-text publication rate of studies reported as 2013 SoFCOT meeting abstracts
Roger Erivan -
Surgical strategies during the COVID-19 crisis: The Salzburg concept
J. Presl -
Surgical strategies during the COVID-19 crisis: The Salzburg concept
J. Presl -
Contemporary resuscitation of hemorrhagic shock: What will the future hold?
Amanda M. Chipman -
Contemporary resuscitation of hemorrhagic shock: What will the future hold?
Amanda M. Chipman -
Investigation of the Association between the Oral and the Gut Microbiome in Glaucoma
Miriam Kolko -
Investigation of the Association between the Oral and the Gut Microbiome in Glaucoma
Miriam Kolko -
Significance of Serum Copper Levels in Patients with Acne Vulgaris
Butool F1 and Amanullah M -
Significance of Serum Copper Levels in Patients with Acne Vulgaris
Butool F1 and Amanullah M -
Investigation of metabolism of exogenous glucose at the early stage and onset of diabetes mellitus in otsuka long-evans tokushima fatty rats using [1,2,3-13c] glucose breath tests
Yoshihisa Uritaa, Naoyuki Kawagoea, Sho Kijimaa, Hideki Tanakaa, Naoyasu Kashimaa, Katsuhito Kashiwagia, Taizo Takeuchia, Takahiro Saitoa, Fumiya Komatsua, Atsuhito Yamadaa, Kenshi Suzukia, Eri Kumadea, Ikutaka Takemotoa, Yosuke Sasakia, Tadashi Maedaa, Takamasa Ishiia, Toshiyasu Watanabea, Taito Miyazakia, Hiroaki Zaia and Hitoshi Nakajimaa -
Investigation of metabolism of exogenous glucose at the early stage and onset of diabetes mellitus in otsuka long-evans tokushima fatty rats using [1,2,3-13c] glucose breath tests
Yoshihisa Uritaa, Naoyuki Kawagoea, Sho Kijimaa, Hideki Tanakaa, Naoyasu Kashimaa, Katsuhito Kashiwagia, Taizo Takeuchia, Takahiro Saitoa, Fumiya Komatsua, Atsuhito Yamadaa, Kenshi Suzukia, Eri Kumadea, Ikutaka Takemotoa, Yosuke Sasakia, Tadashi Maedaa, Takamasa Ishiia, Toshiyasu Watanabea, Taito Miyazakia, Hiroaki Zaia and Hitoshi Nakajimaa
Conference Proceedings
-
Polymeric microcarriers for the tunable co-delivery of two incompatible APIs
Christophe A Serra,Ikram Ullah Khan, Nicolas Anton and Thierry F VandammeKeynote: Asian Journal of Biomedical and Pharmaceutical Sciences
-
Polymeric microcarriers for the tunable co-delivery of two incompatible APIs
Christophe A Serra,Ikram Ullah Khan, Nicolas Anton and Thierry F VandammeKeynote: Asian Journal of Biomedical and Pharmaceutical Sciences
-
RELATIONSHIP BETWEEN COGNITIVE ABILITY AND VASCULAR AGE AND STRESS
Kazue Sawami, Tetsuro Kitamura and Chizuko SuishuPosters & Accepted Abstracts: Biomedical Research
-
RELATIONSHIP BETWEEN COGNITIVE ABILITY AND VASCULAR AGE AND STRESS
Kazue Sawami, Tetsuro Kitamura and Chizuko SuishuPosters & Accepted Abstracts: Biomedical Research
-
VACCINATION AGAINST YELLOW FEVER IN A PATIENT ON IMMUNOBIOLOGICAL WITH DIAGNOSIS OF PSORIATIC ARTHRITIS
Patricia Avila FabriniScientific Tracks Abstracts: Biomedical Research
-
VACCINATION AGAINST YELLOW FEVER IN A PATIENT ON IMMUNOBIOLOGICAL WITH DIAGNOSIS OF PSORIATIC ARTHRITIS
Patricia Avila FabriniScientific Tracks Abstracts: Biomedical Research
-
The p52 isoform of Shc1 is a key driver of Breast Cancer initiation
Andrey SorokinPosters & Accepted Abstracts: Journal of Medical Oncology and Therapeutics
-
The p52 isoform of Shc1 is a key driver of Breast Cancer initiation
Andrey SorokinPosters & Accepted Abstracts: Journal of Medical Oncology and Therapeutics
-
HAT1 ENHANCES HEPATOCARCINOGENESIS THROUGH MODULATION OF EPIGENETIC MODIFICATION
Guang YangPosters & Accepted Abstracts: Journal of Gastroenterology and Digestive Diseases
-
HAT1 ENHANCES HEPATOCARCINOGENESIS THROUGH MODULATION OF EPIGENETIC MODIFICATION
Guang YangPosters & Accepted Abstracts: Journal of Gastroenterology and Digestive Diseases
-
Integrating advance care planning education early in cirrhosis care: An interdisciplinary model to increase uptake
Amanda J Brisebois -
Integrating advance care planning education early in cirrhosis care: An interdisciplinary model to increase uptake
Amanda J Brisebois -
Breast MRI; Updated indications
Tarek ArefScientific Tracks Abstracts: Journal of Medical Oncology and Therapeutics
-
Breast MRI; Updated indications
Tarek ArefScientific Tracks Abstracts: Journal of Medical Oncology and Therapeutics
-
Improving patient outcome through personalized radiation immuno-oncology approaches
Mohammad K KhanScientific Tracks Abstracts: Journal of Medical Oncology and Therapeutics
-
Improving patient outcome through personalized radiation immuno-oncology approaches
Mohammad K KhanScientific Tracks Abstracts: Journal of Medical Oncology and Therapeutics